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Abstract 
Background：The clinical impact of salvage surgery after chemotherapy on cancer survival of patients 
with metastatic urothelial carcinoma is controversial. To verify the clinical role of salvage surgery by 
analyzing the long-term outcome in patients with urothelial carcinoma treated by chemotherapy.  
Methods：Between 2003 and 2010, thirty-one of 47 patients (66%) with metastatic urothelial carcinoma 
showed objective responses (CR in 4, PR in 27) after multiple courses of Cisplatin/Gemcitabine 
/Paclitaxel-based chemotherapy, and a cohort of patients with partial response (PR) were retrospectively 
enrolled, at a single institution. Twelve (10 male and 2 female, median age 64.0 yrs) of 27 patients with 
PR underwent salvage surgeries after the chemotherapy: metastatectomy of residual lesions (10 
retroperitoneal lymph nodes, 2 lung), and 6 radical surgeries for primary lesions as well. Progression-free 
survival and over-all patient survival rates were analyzed retrospectively and compared with those of 
patients without salvage surgery.  
Results： All 12 patients achieved surgical CR. Pathological findings of metastatic lesions showed 
viable cancer cells in 3 patients. In univariate analysis, sole salvage surgery affected over-all survival in 
27 patients with PR to the chemotherapy (p=0.0037). Progression-free survival and over-all survival rates 
in patients with salvage surgery were better than those in 15 PR patients without the surgery (39.8% vs 
0%, and 71.6% vs 12.1% at 3 years, p = 0.01032 and 0.01048; log-rank test).  
Conclusions：Salvage surgery for patients with residual tumor who achieve partial response to 
chemotherapy could have possible impact on cancer survival.  
 
Mini-abstract 
 
 Salvage surgery for patients with residual tumor who achieved partial response to the chemotherapy 
could have possible impact on cancer survival.  
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Introduction  
Modern cisplatin-based combination systemic chemotherapies for metastatic urothelial cancer have 
shown over-all response rates of approximately 50–70% with median survival of about 13 months [1-5]. 
Of these chemotherapies, methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) had been the 
standard regimens for initially unresectable or metastatic urothelial cancer. Recently, the combination of 
gemcitabine/cisplatin (GC) has become a new standard treatment in metastatic urothelial cancer in Europe 
and North America, based on randomized trials showing similar survival but having a more favorable 
toxicity profile for GC when compared to MVAC[5]. 
Although chemotherapy can achieve relatively high response rates in patients with metastatic 
urothelial cancer, fewer patients, even responders, can survive long-term by chemotherapy alone [6]. As 
part of a multidisciplinary approach, salvage surgery for residual metastatic masses after chemotherapy 
may improve prognoses of patients with metastatic urothelial cancer. Cowles et al, writing on the concept 
of surgical treatment for metastatic urothelial cancer, reported a median 5-year survival rate for six 
patients following thoracotomy for solitary pulmonary metastatic lesion [7]. Due to the promising 
responses to chemotherapy, the therapeutic concept of surgery for metastatic urothelial cancer has been 
addressed again, a decade after the initial reports [8-14].  These reports support the therapeutic approach 
by surgical resection of metastatic lesion in patients with metastatic urothelial cancer. In addition, most 
tumor relapses after an initial response to systemic chemotherapy occur at prior sites of disease, which 
provide a possible rationale for salvage surgery of these residual masses [15]. Cisplatin/Gemcitabine-
based chemotherapy allows salvage surgery immediate following treatment due to its mild toxicity. 
However, the clinical impact of salvage surgery on survival benefit in responders to chemotherapy is still 
controversial. In this study, we verify the clinical role of salvage surgery by analyzing long-term outcome 
in patients with metastatic urothelial cancer treated by Cisplatin/Gemcitabine-based chemotherapy, 
focusing especially on a cohort of patients with partial response (PR), at a single institution. 
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Patients and Methods 
Between 2003 and 2010, 47 patients with metastatic urothelial cancer (34 male and 13 female, median 
age 64.2 yrs) were treated by systemic Cisplatin/Gemcitabine/Paclitaxel based chemotherapy [16]: 
Gemcitabine 1000mg/m2 plus Paclitaxel 80mg/m2 on days 1 and 8 and Cisplatin 70mg/m2 on day 1 as 
GCP therapy (1-8 courses; median 3 courses) at our hospital with the approval of our Institutional Cancer 
Board. Seven patients were treated without Paclitaxel, and two were treated without Gemcitabine, due to 
the drug allergy. All patients had distant metastases (visceral metastases or distant lymph node (LN) 
metastasis) and 19 had simultaneous advanced primary lesions. Fourteen patients received MVAC as 
prior chemotherapy before the GCP therapy.  Thirty-one of the 47 patients (66%) showed objective 
responses in RECIST criteria (complete response (CR) in 4, PR in 27) after multiple courses of the 
chemotherapies.  
In this study, we focused on and analyzed the cohort of patients with PR to the chemotherapy.  Twelve 
of 27 patients with PR underwent salvage surgeries after chemotherapy (10 male and 2 female, median 
age 64.0 yrs). These patients underwent salvage surgery for residual lesions (10 retroperitoneal LNs, 2 
lung). All six patients with simultaneous primary lesions underwent radical surgeries for primary lesions 
as well. Resections of metastatic urothelial cancer to render patients free of disease were regarded as 
salvage surgery; resections only for the purpose of symptom palliation were not. 
Salvage surgery was generally considered in situations where patients had residual visceral metastases in 
a solitary organ with a small number of lesions and/or residual distant LN metastases after good response 
(PR) to the chemotherapies and good performance status (PS), although we did not have strict prospective 
criteria.  All therapeutic decisions were left to the discretion of our department on the basis of individual 
clinical features and patient request for aggressive treatment. 
Patient progression-free survival and over-all survival rates were analyzed retrospectively.  Survival 
was measured from the time of initiation of chemotherapy until death or the last follow-up. Clinical 
features were examined by univariate analysis for their association with survival. Variables considered 
were sex (male or female), age (≤65 yr or >65 yr), primary site (bladder alone or other), radical resection 
of primary lesion (yes or no), number of metastatic organs (single or multiple), LN metastasis (yes or no), 
lung metastasis (yes or no), presence of liver or bone metastasis (yes or no), and salvage surgery (yes or 
no).  Survival curves were estimated by Kaplan-Meier method and survival distributions were compared 
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by the log-rank test; p < 0.05 was considered significant. 
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Results 
Patients with PR to chemotherapy 
The summary of characteristics of the 27 patients with PR to the chemotherapies is shown in Table 1. 
Eighteen patients had metastases at diagnosis of urothelial cancer, while metastases developed in 9 after 
the primary site had been treated surgically (radical surgery in 7; transurethral resection in 2). Patients 
received 3-9 courses of GCP therapy. Thirteen of PR patients died of cancer and the remaining 14 survive. 
The over-all and cause-specific survival rates were 84.6% at 1 year and 56.4% at 2 years, respectively. 
Fifty-percent survival duration was 26.0 months. Four patients with clinical CR survived without 
recurrence or progression. 
Patients with salvage surgery 
Twelve patients underwent salvage surgery after chemotherapy. Patient details are shown in Table 2.  
Median age was 64.0 years old (range: 41–73). The primary tumor site was the bladder in 4 patients and 
upper urinary tract in 8. Five had single metastatic lesions and seven had multiple lesions. Nine (75%) 
patients with salvage surgery underwent adjuvant chemotherapy (2-3 courses of GCP chemotherapy). As 
for pathological findings in the salvage surgical specimens of metastatic lesions, viable cancer cells were 
recognized in 3 patients (1 in lung, and 2 in LN) whereas necrotic tissues were confirmed in the other 9. 
Univariate analysis 
Although gender, primary site, resection of primary site, number of metastatic organs, and metastatic site 
did not affect progression-free survival, salvage surgery and age did. As for over-all/cause-specific 
survival, sole salvage surgery affected it strongly (p = 0.0037) (Table 3). 
Figure 1a shows Kaplan-Meier progression-free survival curve with or without salvage surgery. 
Progression-free survival rates at 2 and 3 years in patients with salvage surgery were 63.6% and 39.8%, 
respectively and significantly longer than those in patients without salvage surgery (7.3% at 2years, p = 
0.01032).  Figure 1b shows Kaplan-Meier over-all/cause-specific survival curve with or without salvage 
surgery. The 3- and 5-year survival rates in patients with salvage surgery were both 71.6% and 
significantly longer than those in patients without salvage surgery (12.1%, p = 0.01048). 
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Discussion 
Recently several authors have reported on the benefits of surgical resection of metastatic sites during a 
multidisciplinary approach for metastatic urothelial cancer [8-14]. Dodd et al [8] reported that a 5-yr over-
all survival rate of 33% was achieved in 50 patients with a major response to initial chemotherapy. In an 
up-dated series from the institute, 58% of patients who underwent post-chemotherapy surgery survived 
from 9 months to 5 years, while one of 12 patients (8%) who refused surgery remained alive [10]. They 
concluded that chemotherapy plus surgical resection of residual cancer to attain a complete response is 
critical for long-term survival in select patients who would otherwise die of recurrent disease. The authors 
also described in their data that only one third of the patients were deemed to be candidates for post-
chemotherapy surgery, and of these, about one third survived [15], meaning that post-chemotherapy 
surgery could save about 1 or 2 out of every 10 patients treated. Our results show that one quarter of 
patients with metastatic urothelial cancer were candidates for salvage surgery and are similar to or 
relatively less than the rates described above. In our study, an influence by bias of patients’ selection for 
salvage surgery on the results should be considered. The patients underwent salvage surgery might be a 
cohort of relatively low risk of recurrence compared to the patients who could not undergo. No visceral 
metastasis except lung was treated by salvage surgery, and high rate (10/12) of patient with salvage 
surgery had retroperitoneal lymphnodes swelling alone. The difference of patients’ backgrounds might 
affect on the outcome even statistical analysis in our small study could not reveal it. However, even 
considering the selection bias, survival benefits for patients with salvage surgery were so apparent in our 
series that we regard salvage surgery as a strong method in important addition to a multidisciplinary 
approach for metastatic urothelial cancer. 
The pathological findings of our surgical specimens showed a higher incidence (9 of 12 patients) of non-
viable cancer cells than in prior reports: 33% in the Memorial Sloan-Kettering Cancer Center [10] and 
18% in the German Group [14].   Our patients were treated by Cisplatin/Gemcitabine/paclitaxel-based 
chemotherapy (GCP), which differs from prior reports where MVAC therapy mainly was used. In 
addition, four clinical CR patients survived without recurrence. The high rate of pathological CR might be 
a reason for the high rate of survival in our series. On the other hand, the pathological findings may lead a 
speculation that the patients underwent salvage surgery have a bias for relatively low risk of recurrence 
compared to the patients who could not undergo salvage surgery. Although these speculations may imply 
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that salvage surgery for residual mass could be over-treatment for patients with only scarring in the 
specimen, we believe, as investigators have pointed out [10, 17], that salvage surgery is still worthwhile; 
negative pathology could also mean that residual nests of microscopic tumors were simply not detected in 
a large fibrotic specimen. On the other hand, surgery for metastatic sites where clinical CR was achieved 
by GCP therapy is still controversial, although the primary site should be removed even if showing 
clinical CR.  
The main issue is to identify patients most likely to benefit from salvage surgery [17]. Surgical resection 
has to be technically feasible and the number of metastatic foci limited. Salvage surgery should be 
curative. With palliative intent, Otto et al reported on 70 patients undergoing resection of metastatic 
lesions after proving refractory to M-VAC chemotherapy [19]. While symptomatic patients experienced at 
least some relief, asymptomatic patients showed no beneficial palliative effects. Surgery with palliative 
intent is not beneficial and patients who failed to respond to chemotherapy did not survive in prior reports. 
The response to systemic chemotherapy is therefore important for survival for patients treated with a 
multidisciplinary approach. Although our study is small and retrospective, salvage surgery should only be 
offered to patients with a major response to chemotherapy where complete resection of all detectable 
masses seems feasible. In addition, since post-chemotherapy radiographs and scans are still unable to 
distinguish patients who have no evidence of residual pathologic disease from those who do, it seems 
reasonable to consider salvage surgery in patients with a major response to chemotherapy.  In our small 
number of patients with complete response to GCP therapy, long progression-free survival rates were 
obtained without additional surgery. Surgery for metastatic sites remains controversial.  
As for objective sites in salvage surgery, as Herr et al described [18], limited nodal or a solitary visceral 
or lung lesion is most likely to benefit from surgical resection.  Patients with multiple liver metastases or 
metastases involving more than one visceral site or abdominal organ or bone metastases, especially 
involving the pelvis or axial skeleton, might not be a candidate of salvage surgery even if showing a 
major response to chemotherapy since prognoses in such patients were poor in prior reports.  However, 
positron emission tomography (PET) scans may help to identify residual viable cancer, providing an 
indication for salvage surgery to a sole residual site in such patients in future. Finally, patient motivation 
and stamina for aggressive treatment may be the most important factors for salvage surgery.  
Conclusions 
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Salvage surgery for patients with residual tumor who achieve partial response to chemotherapy could 
have a possible impact on cancer survival. 
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Table 1  
 
Sex 
 
 
Age 
 
Primary site 
 
 
Metastatic sites 
 
 
 
 
 
Follow up 
 
Male 
Female 
 
41-76yr(median 64.0) 
 
Upper urinary tract 
Bladder 
 
Lung 
Retroperitoneal lymph node 
Contrarateral kidney 
Liver 
Bone 
 
4.5-66.0 mo(median 17.4) 
20 
  7 
 
 
 
15 
12 
 
12 
17 
  1 
  4 
  1 
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Table 2  
 
Sex 
 
 
Age 
 
 
Primary site 
 
 
Metastatic sites 
 
 
Salvage surgery 
 
 
Follow up 
 
Male 
Female 
 
41-73yr(median 57.0) 
 
 
Upper urinary tract 
Bladder 
 
Lung 
Retroperitoneal lymph node 
 
Pulmonary metastatectomy 
RPLND 
 
4.5-66.0mo(median 33.6) 
 9 
 3 
 
 
 
 
 8 
 4 
 
 2 
10 
 
 2 
10 
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Table3  
 
 Patient 
Number
Cause-specific survival 
(median) months 
Time to progression. 
(median) months 
Sex 
 male 
 female 
Age 
 ≤65 
 >64 
 
Primary site 
 Upper urinary tract 
 Bladder 
Resection of primary site 
 yes  
 no 
Resection of metastasis 
 yes 
 no 
Number of metastatic organ 
 1 
 2 or more 
 
Metastatic site 
Lymph node 
 yes 
 no 
Lung 
 yes 
 no 
Liver 
 yes 
 no 
 
 
20 
   7 
 
12 
15 
 
 
15 
12 
 
20 
   7 
 
12 
15 
 
20 
   7 
 
 
 
19 
   8 
 
12 
15 
   
5 
22  
 
 
4.5-62.4(37.9)    p=0.627423
7.4-66.0(38.2) 
 
7.7-66.0(22.0)    p=0.266397
4.5-62.3(14.5) 
 
 
4.5-66.0(37.4)  p=0.969227
7.7-62.3(45.4) 
 
4.5-66.0(47.2)  p=0.236936
7.7-40.0(24.4) 
 
4.5-66.0(47.2)  p=0.003691
7.7-40.0(24.4) 
 
4.5-66.0(37.9)  p=0.15698 
8.4-38.7(24.6)  
 
 
 
7.7-66.0(36.4)  p=0.457592
4.5-62.3(15.2) 
 
4.5-62.3(26.1)  p=0.129457
7.7-66.0(37.1) 
 
8.8-19.9(12.3)  p=0.129379
4.5-66.0(37.9) 
 
 
3.8-56.1(24.8)    p=0.918485
6.2-43.4(35.2) 
 
3.8-43.4(27.3)  p=0.045829
2.6-56.1(13.0) 
 
 
3.0-43.7(23.5)  p=0.819823
2.6-56.1(14.6) 
 
3.0-56.1(25.6)  p=0.171848
3.8-30.3(12.5) 
 
3.0-56.1(23.0)  p=0.002953
2.6-30.3(14.6) 
 
2.6-56.1(25.6)  p=0.328646
5.2-32.9(19.6) 
 
 
 
3.8-43.7(12.5)  p=0.777152
2.6-56.1(25.6) 
 
2.6-56.1(21.7)  p=0.278525
3.8-43.7(18.2) 
 
6.2-17.6(9.7)   p=0.296174
2.6-56.1(19.2) 
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Table captions 
Table1 Characteristics of the 27 patients with PR to the chemotherapy 
Table2 Characteristics of the 12 patients with salvage surgery after the chemotherapy 
Table3 Results of univariate analysis 
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Figure 1a 
 
 
Figure 1b 
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